Search Bar & Filters
Found 181 Actively Recruiting clinical trials
Actively Recruiting
Researchers are exploring a new treatment for chronic myeloid leukemia CML, a type of blood cancer. The study aims to evaluate the safety and tolerability of different doses of MK-4208 Tern-701 and to identify the highest dose that participants can tolerate and that may be effective in treating CML. This trial is being conducted in phases 1 and 2 to gather important information about MK-4208s use in this disease. Participants will receive MK-4208 orally at various doses ranging from 160 mg to 500 mg, taken once or twice daily depending on the study part. The study includes multiple groups that receive different doses to compare safety and tolerability. Treatment duration and dosing schedules may vary across the study parts, with careful monitoring of participants during the intervention. Throughout the study, participants will undergo regular assessments including monitoring for dose-limiting toxicities, adverse events, and serious side effects up to three years. Researchers will also track hematologic and molecular responses to the treatment and measure drug levels in the blood over time. Safety, tolerability, and efficacy data will be collected to better understand the potential role of MK-4208 in treating CML, with the study expected to last until 2030 for complete follow-up.
Actively Recruiting
Researchers are studying the safety and effectiveness of a drug called tacabrutideg for people with B-cell malignancies, a type of cancer that affects white blood cells. These cancers include various forms such as chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma, and others. The study aims to find the best dose of tacabrutideg and evaluate how well it works in shrinking or eliminating these cancers. The study has two parts first, a dose escalation phase where different doses of tacabrutideg are tested to find a recommended dose that is safe and tolerable. Then, an expansion phase enrolls more participants to further assess the safety and effectiveness of the selected dose or doses. Tacabrutideg is given orally. The study includes multiple groups of participants with different types of B-cell malignancies, including some specific cohorts like Japanese participants and those who have not previously received certain kinase inhibitors. Participants will visit clinics regularly over about three years for treatment, health checks, blood tests, tumor imaging, and other assessments. Researchers will monitor side effects, measure cancer response, and collect blood samples to study how the drug behaves in the body. The main outcomes include safety, identifying the best dose, and overall cancer response rates. The study is open label, so both participants and doctors know the treatment given.
Actively Recruiting
Researchers are studying the use of unlicensed cryopreserved cord blood units CBUs for transplantation in both children and adults with blood cancers and other related disorders. This observational study involves patients with hematologic malignancies and various inherited and acquired disorders affecting the blood and immune system. The main goal is to monitor how well neutrophil recovery occurs after transplantation using these unlicensed CBUs in multiple institutions. Participants receive unlicensed cryopreserved CBUs as part of their transplant treatment. The study includes patients of any age receiving these CBUs for approved indications. The protocol focuses on the access and distribution of these unlicensed units rather than a specific treatment intervention. The study gathers data from recipients who receive these CBUs, tracking outcomes after transplantation. Participants are monitored for neutrophil recovery at 60 and 100 days after transplant, defined by a neutrophil count of at least 500mm3. Researchers also collect information on infection transmission, infusion reactions, survival rates at one year, and incidence of acute and chronic graft versus host disease. Platelet recovery is also evaluated. Safety and efficacy outcomes are followed over time to better understand the effects of unlicensed CBUs in this patient population.
Actively Recruiting
Researchers are conducting a Phase 12, first-in-human, open-label study of BHV-1510, an antibody-drug conjugate targeting Trop-2, in participants with advanced solid tumors that have been previously treated. The study aims to evaluate the safety, tolerability, and preliminary effectiveness of BHV-1510 alone and in combination with cemiplimab, an anti-cancer agent, in patients with tumors resistant to standard therapies. This trial is multicenter and sponsored by Biohaven Therapeutics Ltd. The study has two parts Phase 1 includes dose escalation to determine safe and tolerable doses of BHV-1510 as monotherapy and combined with cemiplimab, identifying recommended doses for expansion and maximum tolerated doses. Phase 2 expands to evaluate preliminary effectiveness in different tumor cohorts using the established doses. BHV-1510 is administered intravenously in different schedules every 2 or 3 weeks, sometimes with doses on Day 1 and Day 8, and cemiplimab is given as a 350mg IV infusion every 3 weeks, alone or in combination. Participants will undergo regular assessments including monitoring adverse events throughout the study, pharmacokinetic blood sampling at specific time points, and tumor response evaluations using established criteria. The study tracks objective response rates, duration of response, and survival outcomes over an average of 47 months. Safety, drug levels, and immune responses are closely monitored. The total trial duration may extend up to approximately 47 months, ensuring comprehensive evaluation and follow-up of participant outcomes.
Actively Recruiting
Researchers are evaluating DISC-3405, a drug given by subcutaneous injection, in adults with sickle cell disease SCD. This open-label, phase 1b study is designed to assess the safety, tolerability, pharmacokinetics PK, and pharmacodynamics PD of up to three different dose levels of DISC-3405 in participants with SCD. The study is sponsored by Disc Medicine, Inc and is focused on treatment outcomes in this population. Participants will receive DISC-3405 with doses gradually increased within the same participant to evaluate different levels. The study will monitor how the drug behaves in the body and its effects on various blood parameters related to sickle cell disease. This dose-escalation approach allows researchers to gather detailed information on safety and biological responses across up to three dose levels. During the study, participants will undergo assessments including blood tests to measure hemoglobin, hematocrit, reticulocyte count, red blood cell count, lactate dehydrogenase, and bilirubin levels. Pharmacokinetic measurements such as drug concentration over time will also be collected. Safety and tolerability will be closely monitored for up to 36 weeks. Participants must be able to understand and comply with study procedures, and their health status will be regularly evaluated throughout the trial.
Actively Recruiting
Researchers are studying the safety and effectiveness of NEU-411 in people aged 40 to 80 years with early Parkinsons Disease PD who have a specific genetic profile that predicts increased activity in the LRRK2 pathway. This Phase 2 study uses a companion diagnostic genetic test to identify participants with LRRK2-driven PD. The trial aims to compare NEU-411, a brain-penetrant drug that inhibits LRRK2 activity, to a placebo. Participants will be randomly assigned to receive either NEU-411 30 mg once daily or a matching placebo for 52 weeks. After this double-blind treatment period, there will be a safety follow-up visit within two weeks. Those who qualify may continue into an open-label extension phase where they will receive NEU-411 for an additional 26 weeks. Throughout the study, participants will have their Parkinsons symptoms and safety monitored using digital biomarker scores and clinical rating scales. Researchers will assess changes from baseline in the Roche digital biomarker score and the Unified Parkinsons Disease Rating Scale over the 52-week treatment period. Safety will be tracked by recording adverse events through the end of the study. Total participation may last up to 78 weeks including the extension and follow-up.
Actively Recruiting
Researchers are investigating the effects of APL-3007 combined with SyfovrePegcetacoplan APL-2 in patients with geographic atrophy caused by age-related macular degeneration AMD. This Phase 2 randomized, placebo-controlled study aims to assess the efficacy, safety, tolerability, and pharmacodynamics of these treatments in this eye condition. The study involves multiple centers and uses a masked design to ensure unbiased results. Participants will be assigned to one of three groups two receiving different doses or frequencies of APL-3007 in combination with pegcetacoplan APL-2, and one receiving a placebo along with pegcetacoplan APL-2. The study will evaluate the treatments given as multidose regimens. The treatments focus on complement C3 inhibition to potentially impact disease progression. Throughout the study, participants will undergo assessments including artificial intelligence-based imaging to measure retinal pigment epithelium lesion area and photoreceptor degeneration, safety evaluations through adverse event reporting and visual acuity tests, and blood tests to assess serum markers. These evaluations occur over 12 months to monitor changes from baseline. Participants involvement includes regular visits for these assessments, with the study tracking treatment effects and safety over the duration.
Actively Recruiting
Researchers are evaluating the safety and effects of a medicine called Fosmanogepix for treating candidemia and invasive candidiasis, serious fungal infections caused by Candida species. This Phase 3 study compares Fosmanogepix with standard treatments to see if it works at least as well as current therapies. The trial involves adult patients diagnosed with these infections, aiming to assess treatment success and patient survival. Participants receive one of two treatments two-thirds get Fosmanogepix through an intravenous IV infusion daily at the clinic, with an option to switch to oral tablets if well enough to continue treatment at home. One-third receive the standard care of Caspofungin IV infusion followed by oral Fluconazole capsules. Matching placebos are used for blinding. Treatment can last up to 6 weeks depending on infection clearance and symptom improvement. During the study, participants undergo regular assessments including blood tests and monitoring for treatment success and safety. Researchers measure survival at 30 days and response rates at multiple time points, including after treatment ends and at a 6-week follow-up. The study tracks adverse events, lab abnormalities, and drug levels to evaluate safety and treatment effects. Total participation can last up to about 12.5 weeks with follow-up visits to monitor long-term outcomes.
Actively Recruiting
Researchers are evaluating the use of pemigatinib for adults with advanced or metastatic pancreatic cancer that has spread locally or to distant parts of the body. This study focuses on patients whose cancer has specific abnormal changes in the FGFR gene, which can promote cancer growth. The goal is to see if pemigatinib can block these abnormal genes to stop tumor growth and improve quality of life. Participants take pemigatinib orally once daily for 14 days in each 21-day cycle, continuing as long as the cancer does not worsen or side effects are manageable. During the study, patients undergo blood tests, CT andor MRI scans, and optical coherence tomography OCT. Additional scans like whole body bone scans and eye exams may be performed if needed. After treatment, patients are followed up 30 days later and then every 4 months for one year. Throughout the study, researchers assess tumor response using imaging and blood tests, including monitoring cell-free DNA to track response and resistance. They measure overall response rate up to 24 months and evaluate progression-free survival, disease control, overall survival, and side effects up to 12 months. Safety and tolerability are closely monitored, and patients overall health and treatment effects are regularly checked to understand the impact of pemigatinib.
Actively Recruiting
Researchers are evaluating the inhalation suspension of ensifentrine, given twice daily via a standard jet nebulizer, for its effects on people with non-cystic fibrosis bronchiectasis NCFBE. This randomized, double-blind, placebo-controlled Phase II study aims to assess the safety and efficacy of ensifentrine compared to placebo over up to 52 weeks. The main focus is to see how ensifentrine affects lung flare-ups, symptoms, and quality of life in participants who continue their standard care. Participants will be randomly assigned to receive either 3 mg of nebulized ensifentrine or a matching placebo, both administered twice daily through a jet nebulizer for up to 52 weeks. Neither participants nor study staff will know which treatment is given. Some participants may finish earlier if the study ends after the last participant completes the 24-week visit. This trial compares the study drug to placebo while all participants receive their usual care. During the study, participants will be monitored regularly with lung function tests, symptom questionnaires, and quality of life assessments at baseline and at several points up to 24 weeks and through study completion. Researchers will measure the rate of lung exacerbations and track adverse events for up to 52 weeks. Additional pharmacokinetic tests will be done in a sub-study. Participants will be expected to perform spirometry and provide sputum samples, and their medication adherence and safety will be closely followed throughout the study period.
1-10 of 181
1